

# Partnering Activity Update

**Oct 30, 2020**

# Cautionary Notes

***Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable.***

***Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to:***

- ( i ) failures in new product development***
- ( ii ) changes in general economic conditions due to reform of medical insurance system***
- ( iii ) failures in obtaining the expected results due to effects of competing products or generic drugs***
- ( iv ) infringements of the Company's intellectual property rights by third parties***
- ( v ) stagnation of product supply from the delay in production due to natural disasters, fires and so on***
- ( vi ) onset of new side effect of post-licensure medical product***
- and, ( vii ) currency exchange rate fluctuations and interest rate trend.***

***Information about pharmaceutical products (including products currently in development) included in this document is not intended to constitute an advertisement of medical advice.***



# Partnering Activity (2010~) (1)

As of Oct 27, 2020

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Sep 2010	KYPROLIS (Carfilzomib)	Multiple Myeloma (Proteasome inhibitor)	L	L	Amgen, USA (in-license/JPN)
Sep 2011	CORALAN (Ivabradine)	Chronic Heart Failure (HCN channel blocker)	L	L	Servier, France (in-license/JPN)
	PARSABIV (Etelcalcetide)	Secondary Hyperparathyroidism (Calcium sensing receptor agonist)	L	L	Amgen, USA (in-license/JPN)
	OPDIVO (Nivolumab)	Melanoma, NSCLC, RCC Hodgkin's Lymphoma H&N Cancer, Gastric Cancer Esophageal cancer, Colorectal cancer (MSI-H), etc. (Anti-PD-1 mAb)	L	L	BMS, USA (out-license/except JPN, KOR & TWN)
	ORENCIA (Abatacept)	Rheumatoid Arthritis Juvenile Idiopathic Arthritis (T cell activation inhibitor)	L	L	BMS, USA (in-license/JPN)
Apr 2013	ONGENTYS (Opicapone)	Wearing-off phenomenon in Parkinson's Disease (COMT inhibitor)	L	L	Bial, Portugal (in-license/JPN)
Oct 2013	DEMSEER (Metyrosine)	Status of Catecholamine Excess Secretion in Pheochromocytoma (Tyrosine hydroxylase inhibitor)	L	L	Bausch Health, USA (in-license/JPN)



# Partnering Activity (2010~) (2)

As of Oct 27, 2020

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Dec 2013	FORXIGA (Dapagliflozin)	Type 2 Diabetes, Type 1 Diabetes (SGLT-2 inhibitor)	L	L	AstraZeneca, UK (in-license/JPN)
		Heart Failure (SGLT-2 inhibitor)	Filing	L	
Jul 2014	OPDIVO (Nivolumab)	Melanoma, NSCLC, RCC, Hodgkin's Lymphoma, H&N Cancer, Gastric Cancer, Esophageal cancer, Colorectal cancer (MSI-H), etc. (Anti-PD-1 mAb)	L	L	BMS, USA (out-license/JPN, KOR & TWN)
	ONO-4578	Solid Tumors (EP4 antagonist)	I	I/II	
	YERVOY (Ipilimumab)	Melanoma, RCC (Anti-CTLA-4 mAb)	L	L	BMS, USA (in-license/JPN, KOR & TWN)
	ONO-4483 (Lirilumab)	Solid Tumors (Anti-KIR mAb)	I	I/II	
	ONO-4482 (Relatlimab)	Melanoma (Anti-LAG-3 mAb)	I/II	II/III	
	ONO-4686 BMS-986207	Solid Tumors (Anti-TIGIT mAb)	I/II	I/II	
	ONO-7701 (Linrodostat)	Bladder Cancer (IDO1 inhibitor)	III	III	
	ONO-7807 BMS-986258	Solid Tumors (Anti-TIM3 mAb)	I/II	I/II	



# Partnering Activity (2010~) (3)

As of Oct 27, 2020

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Jul 2014	ONO-7911 (Bempegaldesleukin)	Solid Tumors (PEGylated IL-2)	I	I/II	BMS, USA (in-license/JPN, KOR & TWN)
		Melanoma, RCC (PEGylated IL-2)	—	III	
	OPALMON (Limaprost $\alpha$ -CD)	Lumber Spinal Canal Stenosis (oral PGE1 analogue)	L	L	Meiji Seika Pharma, JPN (out-license/THA)
Dec 2014	VELEXBRU (Tirabrutinib)	Pemphigus (BTK inhibitor)	II	—	Gilead Sciences, USA (out-license/except JPN, KOR, TWN, CHN & ASEAN)
		B Cell Lymphoma (BTK inhibitor)	—	II	
Mar 2016	ONO-9054 (Sepetaprost)	Glaucoma Ocular Hypertension (FP/EP3 dual receptor agonist)	II	II	Santen Pharmaceutical, JPN (out-license/World-wide)
May 2017	MEKTOVI (Binimetinib) BRAFTOVI (Encorafenib)	BRAF-mutant Melanoma (MEK inhibitor · BRAF inhibitor)	L	L	Pfizer, USA (in-license/JPN & KOR)
		BRAF-mutant Colorectal Cancer (MEK inhibitor · BRAF inhibitor)	Filing	L (BRAFTOVI)	



# Partnering Activity (2010~) (4)

As of Oct 27, 2020


Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Aug 2017	ONO-5704 SI-613	Osteoarthritis (Combined drug of hyaluronic acid and NSAID)	Filing	II	Seikagaku, JPN (in-license/JPN)
		Enthesopathy (Combined drug of hyaluronic acid and NSAID)	II	—	
Jun 2019	ONO-7912 CPI-613 (Devimistat)	Pancreatic Cancer Acute Myeloid Leukemia (Cancer metabolism inhibitor)	I	III	Rafael Pharmaceuticals, USA (in-license/JPN, KOR, TWN & ASEAN)
Jul 2019	ONO-7913 (Magrolimab)	Non-Hodgkin's Lymphoma Acute Myeloid Leukemia Ovarian Cancer, Colorectal Cancer (Anti-CD47 mAb)	I	II	Gilead Sciences, USA (in-license/JPN, KOR, TWN & ASEAN)
		Myelodysplastic syndromes (Anti-CD47 mAb)	I	III	
Oct 2020	(Cenobamate)	Partial-onset seizures (voltage-gated sodium currents inhibitor, γ-aminobutyric acid (GABA <sub>A</sub> ) ion channel modulator)	III	L	SK Biopharmaceuticals, Korea (in-license/JPN)



# Collaboration with BMS for OPDIVO®

**Start collaboration  
in May 2005**


**Expand collaboration  
in Sep 2011**




# Strategic Alliance with BMS in JP, KR & TW

- To Strengthen Immuno-oncology Portfolio
- To Accelerate Combination Therapies

## Co-development




## Co-promotion



Development cost share


Profit/loss allocation





# Collaboration with BMS for ORENZIA®

- Novel Biologic Inhibiting Upstream Inflammation in RA



# Collaboration with AstraZeneca for FORXIGA®

- The First SGLT-2 Inhibitor in the World for Type-2 Diabetes
- In 2019, additional approval for Type-1 diabetes in Japan

